NCT02000154CompletedPhase 1
Phase I Clinical Trial of SyB L-1101 in Patients With Myelodysplastic Syndrome - Extension Study
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- SymBio Pharmaceuticals
- Enrollment
- 1
- Locations
- 2
- Primary Endpoint
- Adverse Events
Study Overview
Brief Summary
This is an extension study study to investigate long term safety of SyB L-1101 when administered intravenously every 4 weeks to the patients who have completed 8 cycles in the study 2011005 whose purpose is to investigate tolerability of SyB L-1101 when administered intravenously in patients with recurrent/relapsed or refractory myelodysplastic syndrome. Antitumor effects will also be investigated in this study.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 20 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients must satisfy the following conditions listed below.
- •Patients enrolled in the study 2011005 of SyB L-1101 in Patients With Myelodysplastic Syndrome.
- •Patients who was not judged as disease progression* nor progressive disease/relapsed** at the end of the cycle 8 in the study
- •* hematologic remission according to IWG 2006 criteria ** hematologic improvement according to IWG 2006 criteria
- •Patients who met the continuation criteria*** after Cycle 8 week 2 (Day 15±3) in the study 2011005.***defined in the study 2011005 protocol
- •Patients who can be expected to survive at least three months or longer.
- •Patients who have score of 0 to 2 in Eastern Cooperative Oncology Grou (ECOG) Performance Status (P.S.).
- •Patients with adequate function in major organs (heart, lungs, liver, kidneys, etc.).
- •Aspartate aminotransferase (AST): no more than 3.0 times the upper boundary of the reference range at each institution
- •Alanine aminotransferase (ALT): no more than 3.0 times the upper boundary of the reference range at each institution
- •Total bilirubin: no more than 1.5 times the upper boundary of the reference range at each institution
- •Serum creatinine: no more than 1.5 times the upper boundary of the reference range at each institution
- •ECG: no abnormal findings requiring treatment
- •Echocardiography: no abnormal findings requiring treatment
- •Patients who personally signed an informed consent document for participation in this study.
Exclusion Criteria
- •Patients who satisfy any of the following conditions will not be enrolled in the study.
- •Patients with anemia (haemolytic anaemia, gastrointestinal haemorrhage, etc.) caused by factors other than MDS.
- •Patients with obvious infectious diseases (including viral infections).
- •Patients with serious complications (liver failure, renal failure, etc.).
- •Patients with a complication of serious heart disease (myocardial infarction, ischemic heart disease, etc.)
- •Patients with a serious gastrointestinal condition (severe or significant nausea/vomiting, diarrhea, etc.)
- •Patients with serious bleeding tendencies (disseminated intravascular coagulation (DIC), internal hemorrhage, etc.).
- •Ascites requiring active medical management including paracentesis, or hyponatremia (defined as serum sodium value of <130 milliequivalent/L).
- •Patients with an addiction to a legal or illegal drug, or with alcohol dependency.
- •Patients who are nursing, pregnant or may become pregnant.
- •Patients who have not consented to the following contraceptive measures. Patients will avoid sexual intercourse with sexual partners or should use the following contraceptive methods in these time periods: for male patients during the administration period of the trial and for six months after the end of administration; female patients during the administration period of the trial, and until a second menstrual period is confirmed after the end of administration (or in the case of female patients with no menstrual period, for two months after the end of administration). (1) Male patients:The patient will always use a condom. For effective contraception, it is recommended that the female partner also use the contraceptive methods for female patients. (2) Female patients: Female patients who may become pregnant should use one or more types of the following contraceptive methods. In addition, the male partner will always use a condom.
- •Oral contraceptive (birth control pills)
- •Intrauterine device (IUD)
- •Tubal ligation
- •Other patients judged to be unsuitable by an investigator or sub-investigator.
Arms & Interventions
SyB L-1101
Experimental
Intervention: SyB L-1101 (Drug)
Outcomes
Primary Outcomes
Adverse Events
Time Frame: Up to 20 weeks
Total number affected by any adverse events (details are presented in adverse event section)
Secondary Outcomes
- Disease Response Assessment(Up to 20 weeks)
- Serious Adverse Events(Up to 20 weeks)
- Hematologic Improvement(Up to 20 weeks)
- Cytogenetic Response(Up to 20 weeks)
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 1
Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension StudyMyelodysplastic SyndromeNCT02002936SymBio Pharmaceuticals1
Completed
Phase 1
Safety and Pharmacokinetics Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)Myelodysplastic SyndromeNCT01700335SymBio Pharmaceuticals9
Completed
Phase 2
Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell LymphomaLow-grade B Cell Non-Hodgkin's LymphomaMantle Cell Lymphoma Where Hematopoietic Stem Cell Transplantation is Not IndicatedNCT01718691SymBio Pharmaceuticals70
Withdrawn
Phase 1
Combination Therapy of SyB C-1101 and Azacytidine in Patients With Myelodysplastic SyndromeMyelodysplastic SyndromeNCT02783547SymBio Pharmaceuticals
Completed
Phase 1
Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)Myelodysplastic SyndromeNCT02014051SymBio Pharmaceuticals10